CN102548571B - 用于预防和治疗脑部疾病和疾病状态的组合物和方法 - Google Patents

用于预防和治疗脑部疾病和疾病状态的组合物和方法 Download PDF

Info

Publication number
CN102548571B
CN102548571B CN201080030502.9A CN201080030502A CN102548571B CN 102548571 B CN102548571 B CN 102548571B CN 201080030502 A CN201080030502 A CN 201080030502A CN 102548571 B CN102548571 B CN 102548571B
Authority
CN
China
Prior art keywords
oegj
brain
extract
treatment
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080030502.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102548571A (zh
Inventor
李明
周震
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generex Pharmaceuticals Inc
Original Assignee
Generex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharmaceuticals Inc filed Critical Generex Pharmaceuticals Inc
Publication of CN102548571A publication Critical patent/CN102548571A/zh
Application granted granted Critical
Publication of CN102548571B publication Critical patent/CN102548571B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
CN201080030502.9A 2009-06-12 2010-06-11 用于预防和治疗脑部疾病和疾病状态的组合物和方法 Expired - Fee Related CN102548571B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18670909P 2009-06-12 2009-06-12
US61/186,709 2009-06-12
US18790509P 2009-06-17 2009-06-17
US61/187,905 2009-06-17
PCT/IB2010/001418 WO2010143063A1 (en) 2009-06-12 2010-06-11 Compositions and methods for prevention and treatment of brain diseases and conditions

Publications (2)

Publication Number Publication Date
CN102548571A CN102548571A (zh) 2012-07-04
CN102548571B true CN102548571B (zh) 2014-08-27

Family

ID=43308481

Family Applications (6)

Application Number Title Priority Date Filing Date
CN201080030502.9A Expired - Fee Related CN102548571B (zh) 2009-06-12 2010-06-11 用于预防和治疗脑部疾病和疾病状态的组合物和方法
CN201080026126.6A Expired - Fee Related CN102740870B (zh) 2009-06-12 2010-06-11 日本路边青有机提取物在制备用于治疗或预防高血压药物中的用途
CN201080030503.3A Expired - Fee Related CN102548560B (zh) 2009-06-12 2010-06-11 用于预防和治疗冠心病的组合物和方法
CN201080026128.5A Expired - Fee Related CN102573865B (zh) 2009-06-12 2010-06-11 用于预防和治疗红细胞聚集的组合物
CN201080026141.0A Expired - Fee Related CN102711768B (zh) 2009-06-12 2010-06-11 用于预防和治疗心衰的组合物和方法
CN201080026127.0A Expired - Fee Related CN102497873B (zh) 2009-06-12 2010-06-11 用于增加生存年限和健康年限的组合物和方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN201080026126.6A Expired - Fee Related CN102740870B (zh) 2009-06-12 2010-06-11 日本路边青有机提取物在制备用于治疗或预防高血压药物中的用途
CN201080030503.3A Expired - Fee Related CN102548560B (zh) 2009-06-12 2010-06-11 用于预防和治疗冠心病的组合物和方法
CN201080026128.5A Expired - Fee Related CN102573865B (zh) 2009-06-12 2010-06-11 用于预防和治疗红细胞聚集的组合物
CN201080026141.0A Expired - Fee Related CN102711768B (zh) 2009-06-12 2010-06-11 用于预防和治疗心衰的组合物和方法
CN201080026127.0A Expired - Fee Related CN102497873B (zh) 2009-06-12 2010-06-11 用于增加生存年限和健康年限的组合物和方法

Country Status (6)

Country Link
US (7) US9950019B2 (enExample)
EP (6) EP2440212A4 (enExample)
JP (11) JP5892929B2 (enExample)
CN (6) CN102548571B (enExample)
AU (11) AU2010258354B2 (enExample)
WO (6) WO2010143062A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105106222A (zh) * 2015-09-14 2015-12-02 新乡医学院 吐曼酸在制备治疗或预防雌激素缺乏引起的阿尔茨海默病药物中的应用
CN106581006A (zh) * 2015-10-16 2017-04-26 香港理工大学深圳研究院 三萜类化合物的应用和治疗帕金森药物

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12397008B2 (en) * 2006-04-13 2025-08-26 Lead Billion Limited Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries
US9950019B2 (en) * 2009-06-12 2018-04-24 Generex Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of brain diseases and conditions
WO2012088264A2 (en) * 2010-12-23 2012-06-28 Huya Bioscience International Llc Purified cardiogenin isomer and related methods
JP6000521B2 (ja) * 2011-08-10 2016-09-28 株式会社ブルボン 血圧上昇抑制剤
EP2812005B8 (en) 2012-05-16 2018-10-31 Prairie Berry Europe GmbH Polyhydroxylated pentacyclic triterpene acids as hmg-coa reductase inhibitors
US20140044813A1 (en) * 2012-08-09 2014-02-13 Kemin Industries, Inc. Plant Extracts for Improving Cognitive Health and Function
CN103623753B (zh) * 2013-11-27 2016-03-23 大兴安岭嘉迪欧营养原料有限公司 大兴安岭野生金老梅总三萜提取物的制备方法
CN103623082B (zh) * 2013-11-29 2016-08-17 江西中医药大学 覆盆子提取物及其应用
US20150174057A1 (en) * 2013-12-24 2015-06-25 Generex Pharamaceutics Inc. Compositions and methods for the prevention and treatment of oral diseases
KR20160113277A (ko) * 2014-01-30 2016-09-28 케민 인더스트리즈, 인코포레이티드 인지 기능을 개선시키기 위한 식물 추출물
CN105311030B (zh) * 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN104971091B (zh) * 2015-06-03 2019-08-13 兴明生物医药技术(上海)有限公司 一种用于制备促进心肌再生药物的提取物的制备方法及其应用
EP3325992B1 (en) 2015-07-24 2026-01-28 Northeastern University Quantitative magnetic resonance imaging of the vasculature
US20180250309A1 (en) * 2015-09-04 2018-09-06 The Board Of Regents Of The University Of Texas System Methods for treatment of monocyte dysfunction and chronic inflammatory micro and macro-vascular diseases
CN106153761B (zh) * 2016-06-07 2018-08-14 贵州师范大学 同时检测无籽刺梨果实中3种黄酮类成分的方法
CA3026162A1 (en) * 2016-06-20 2017-12-28 Butterfly Network, Inc. Automated image acquisition for assisting a user to operate an ultrasound device
CN109562217A (zh) * 2016-11-02 2019-04-02 天普大学-联邦高等教育体系 用于降低血液粘稠度、抑制血液循环中的乱流及治愈缗线状形成的系统及方法
CA3061381A1 (en) * 2017-04-25 2018-11-01 Buck Institute For Research On Aging COMPOSITIONS COMPRISING α-KETOGLUTARATE FOR EXTENDING LIFESPAN AND HEALTHSPAN
CN106946971A (zh) * 2017-04-28 2017-07-14 南宁馨艺荣生物科技有限公司 一种从积雪草中提取积雪草酸的工艺
CN107445855B (zh) * 2017-08-07 2018-12-14 绍兴市逸晨医疗科技有限公司 一种盐酸多西环素杂质c的制备方法
JPWO2019172174A1 (ja) * 2018-03-05 2021-02-12 日本新薬株式会社 Ｒａｇｅシグナル阻害作用をもつ食品素材
TW202000899A (zh) * 2018-03-06 2020-01-01 美商艾沛邦股份有限公司 可注射之即用軟骨、肌腱及韌帶修復組合物及使用方法
EP4741014A3 (en) * 2018-07-27 2026-07-15 Northeastern University Diagnosis of dementia by vascular magnetic resonance imaging
KR102152182B1 (ko) * 2018-09-05 2020-09-04 한국식품연구원 큰뱀무 추출물을 유효성분으로 함유하는 우울 증상 또는 스트레스의 개선, 예방 또는 치료용 조성물
CN112955139B (zh) 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
CN113366032B (zh) 2018-12-21 2024-01-23 阿朗新科新加坡私人有限公司 用于卤化不饱和异烯烃共聚物的湿法中的卤素回收
CA3125548A1 (en) 2019-01-03 2020-07-09 Northeastern University Quantitative measurement of disruptions in the blood brain barrier
CN109884222B (zh) * 2019-01-17 2021-07-13 贵州中医药大学 一种小花清风藤的hplc指纹图谱建立方法
US12642433B2 (en) 2019-01-25 2026-06-02 Northeastern University Quantitative measurement of the perivascular space for CNS and brain disorders
KR102152174B1 (ko) * 2020-03-30 2020-09-04 한국식품연구원 큰뱀무 추출물을 유효성분으로 함유하는 인지기능 장애의 개선, 예방 또는 치료용 조성물
CN111643556A (zh) * 2020-07-16 2020-09-11 杭州科倍安生物制药有限公司 一种用于预防和治疗痔疮的药物及其应用
WO2022043407A1 (fr) 2020-08-25 2022-03-03 Laouarem Yousra Compositions destinées au traitement des troubles neurologiques
KR102574207B1 (ko) * 2020-12-03 2023-09-04 경북대학교 산학협력단 뱀무 추출물을 유효성분으로 하는 혈전성 질환 치료 또는 예방용 조성물
CN112587599A (zh) * 2021-01-11 2021-04-02 贵州中医药大学 一种预防急性高原反应的中药组合物
CN112755079A (zh) * 2021-01-18 2021-05-07 杭州科倍安生物制药有限公司 一种预防血栓形成或溶解已形成血栓的药物及其制备方法
CN113367166B (zh) * 2021-05-13 2022-07-26 海南大学 一种褐背蒲桃提取物杀菌剂及其制备方法和应用
CN114028459A (zh) * 2021-11-11 2022-02-11 杭州科贝生物制药有限公司 预防和治疗哺乳动物缺血性心脏病的药物和制备方法及应用
CN114722066B (zh) * 2022-03-23 2023-04-07 电子科技大学 一种预测材料自旋霍尔电导及反常霍尔电导的方法
CN117257781A (zh) * 2022-06-13 2023-12-22 上海市东方医院（同济大学附属东方医院） 美金刚通过靶向心房心肌细胞谷氨酸受体有效干预房颤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043645A1 (en) * 2001-11-21 2003-05-30 The Chinese University Of Hong Kong Compositions comprising organic extracts of geum japonicum thunb var. and the use thereof
WO2004052381A1 (en) * 2002-12-10 2004-06-24 The Chinese University Of Hong Kong An organic extract of geum japonicum thumb variant and use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP2871763B2 (ja) * 1989-12-15 1999-03-17 株式会社資生堂 テストステロン―５α―レダクターゼ阻害剤
CN1069629A (zh) * 1991-08-27 1993-03-10 段民生 一种康复面的制备方法
CN1047089C (zh) * 1992-12-03 1999-12-08 张斌 治疗近视眼的药物及制备工艺
JPH07179347A (ja) * 1993-12-21 1995-07-18 Showa Shell Sekiyu Kk 抗ウイルス組成物
CN1102993A (zh) 1993-12-21 1995-05-31 吴文才 多酶体系加工中草药的制剂方法
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
WO1998051302A1 (en) 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
CN1176814A (zh) 1997-06-26 1998-03-25 李静 预防和治疗脑血管病的口服液
CN1102399C (zh) 2000-06-09 2003-03-05 张庆玉 降脂通脉胶囊
WO2002007743A2 (de) 2000-07-26 2002-01-31 Vitaplant Ag Piper methysticum pflanzenextrakt
WO2002009720A1 (en) * 2000-07-31 2002-02-07 University Of Virginia Patent Foundation Inhibitors of dna polymerase sigma
US6629835B2 (en) 2000-08-01 2003-10-07 Metaproteomics, Llc Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
JP2002255804A (ja) 2001-03-02 2002-09-11 Suntory Ltd インシュリン様作用を有するヘキサオキシジフェン酸誘導体を含んでなる組成物
JPWO2002078468A1 (ja) 2001-03-30 2004-08-19 日清オイリオ株式会社 血管障害疾患用飲食物
KR100453569B1 (ko) * 2001-09-11 2004-10-20 대한민국 3,4,5-트리히드록시벤즈알데히드를 유효성분으로 포함하는항산화제
JP2003201229A (ja) 2001-10-23 2003-07-18 Shiseido Co Ltd マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料
JP4393777B2 (ja) 2002-03-19 2010-01-06 株式会社ファンケル 抗ヘリコバクター・ピロリ用組成物
CN1239155C (zh) 2003-01-23 2006-02-01 北京中医药大学 一种治疗缺血性脑中风的药物组合物及其制备方法
US20040247698A1 (en) 2003-06-04 2004-12-09 Valenzuela Cortes Carmen Maria Erectile Dysfunction Treatment
KR100751071B1 (ko) 2003-10-10 2007-08-21 에스케이케미칼주식회사 뇌기능 개선 효과를 갖는 트리테르펜계 화합물
CN1185007C (zh) 2003-12-08 2005-01-19 张小朋 降脂溶栓药物
CN100509008C (zh) * 2004-04-12 2009-07-08 赵晓昂 舒痛方及其制剂和用途
WO2006054370A1 (en) 2004-11-16 2006-05-26 Use-Techno Corporation Gluconeogenesis inhibiting agent
KR100704003B1 (ko) * 2005-06-10 2007-04-06 안동대학교 산학협력단 2-알파-하이드록시-올레아놀산을 함유하는 트롬빈 저해혈전증 예방 및 치료용 조성물
JP2006347967A (ja) 2005-06-16 2006-12-28 Yuusu Techno Corporation:Kk 血糖値上昇抑制剤
WO2007049089A1 (en) * 2005-10-27 2007-05-03 Lead Billion Limited Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues
JP4950996B2 (ja) 2005-10-27 2012-06-13 リード ビリオン リミテッド 虚血性心疾患の治療に有用な、血管新生／血行再建のための医薬組成物及び方法
WO2007049088A1 (en) 2005-10-27 2007-05-03 Lead Billion Limited Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues
KR100718602B1 (ko) 2005-12-29 2007-06-21 대한민국 항비만 및 항염증 효과를 가지는 뱀무 추출물, 이를포함하는 식품 조성물 및 이들의 제조 방법
JP2007204447A (ja) 2006-02-03 2007-08-16 Yoshihiro Futamura 中性脂肪減少作用を呈するカルニチン誘導体、それからなる抗肥満薬、食品製剤及びセルライト減少作用を呈する化粧品
JP4731350B2 (ja) 2006-02-17 2011-07-20 丸善製薬株式会社 抗老化剤、皮膚化粧料及び美容用飲食品
CA2646240A1 (en) * 2006-03-16 2007-09-20 Xuemin Shi Combination therapy for treatment of patients with neurological disorders and cerebral infarction
CN1857627B (zh) * 2006-04-12 2010-05-19 贵阳利多药物技术开发有限公司 治疗中风的中药制剂及其制备方法
US8821947B2 (en) 2006-06-01 2014-09-02 Howard W. Selby, III Cholesterol-reducing diet
CN101091751A (zh) 2006-06-22 2007-12-26 北京中医药大学 一种治疗高血压的中药组合物及其制备方法
JP5281234B2 (ja) * 2006-06-27 2013-09-04 ポーラ化成工業株式会社 毛様体過緊張による疲れ目の改善・予防のための経口投与組成物
CN100528195C (zh) * 2006-06-28 2009-08-19 海南晨菲药业有限公司 一种大青根注射剂制备工艺
CN101099770A (zh) 2006-07-04 2008-01-09 北京中医药大学 一种具有咪唑啉受体激动活性的药物组合物及制备方法和应用
JP2008074801A (ja) 2006-09-25 2008-04-03 Oriza Yuka Kk 肝保護剤
JP5366358B2 (ja) * 2006-09-29 2013-12-11 株式会社コーセー 皮膚の老化機構に作用する剤、抗老化用皮膚外用剤、及び抗老化方法
CN101040901A (zh) 2007-04-12 2007-09-26 云南龙润药业有限公司 迷迭香提取物及其制备方法和应用
US9205112B2 (en) 2007-04-23 2015-12-08 Creative Medical Health, Inc. Combination treatment of cardiovascular disease
WO2008144706A2 (en) 2007-05-21 2008-11-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Sweet gum fruit extract as a therapeutic agent
US20090022827A1 (en) 2007-07-19 2009-01-22 Ming Li Agent and method for eliminating malignance of cancer cells without harmful effect to normal cells
CN101125171B (zh) 2007-08-20 2010-05-26 刘凤元 一种男、女补强中药
KR100891881B1 (ko) * 2007-08-23 2009-04-07 대한민국 3,4,5-트리히드록시벤즈알데히드를 유효성분으로 포함하는고지혈증 및 ｍｍｐ 과다활성으로 인한 혈관질환 예방 및치료용 조성물
CN101406537B (zh) 2007-10-11 2013-05-15 首都医科大学 柔毛水杨梅提取物用于制备治疗肥胖的药物的用途
CN101274012B (zh) 2008-01-23 2011-12-28 上海海天医药科技开发有限公司 夏枯草属植物提取物的组合物、制备方法及其药物用途
US9950019B2 (en) 2009-06-12 2018-04-24 Generex Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of brain diseases and conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043645A1 (en) * 2001-11-21 2003-05-30 The Chinese University Of Hong Kong Compositions comprising organic extracts of geum japonicum thunb var. and the use thereof
CN1258371C (zh) * 2001-11-21 2006-06-07 香港中文大学 包括大根草有机提取物的组合物及其应用
WO2004052381A1 (en) * 2002-12-10 2004-06-24 The Chinese University Of Hong Kong An organic extract of geum japonicum thumb variant and use thereof
CN100518745C (zh) * 2002-12-10 2009-07-29 香港中文大学 柔毛水杨梅的有机提取物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
蓝布正对小鼠脑缺血的保护作用;赖泳等;《大理学院学报》;20050930;第4卷(第5期);第44页右栏第1.1节，第45页左栏第2.2、2.3、3.1节以及右栏第4节第7-11行 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105106222A (zh) * 2015-09-14 2015-12-02 新乡医学院 吐曼酸在制备治疗或预防雌激素缺乏引起的阿尔茨海默病药物中的应用
CN105106222B (zh) * 2015-09-14 2020-05-08 新乡医学院 吐曼酸在制备治疗或预防雌激素缺乏引起的阿尔茨海默病药物中的应用
CN106581006A (zh) * 2015-10-16 2017-04-26 香港理工大学深圳研究院 三萜类化合物的应用和治疗帕金森药物
CN106581006B (zh) * 2015-10-16 2019-11-29 香港理工大学深圳研究院 三萜类化合物在制备治疗帕金森药物中的应用

Also Published As

Publication number Publication date
US9629884B2 (en) 2017-04-25
JP2012529483A (ja) 2012-11-22
EP2440212A4 (en) 2013-03-20
US9950019B2 (en) 2018-04-24
JP2015164966A (ja) 2015-09-17
EP2440222A4 (en) 2012-12-12
EP2440212A1 (en) 2012-04-18
JP2015164967A (ja) 2015-09-17
WO2010143063A1 (en) 2010-12-16
AU2010258356A1 (en) 2012-02-02
WO2010143061A1 (en) 2010-12-16
CN102740870A (zh) 2012-10-17
AU2017202573A1 (en) 2017-05-11
JP5892929B2 (ja) 2016-03-23
JP2012529486A (ja) 2012-11-22
EP2440221A1 (en) 2012-04-18
US20120076878A1 (en) 2012-03-29
CN102573865B (zh) 2016-08-24
AU2010258355B2 (en) 2016-04-28
US20120077761A1 (en) 2012-03-29
EP2440220A1 (en) 2012-04-18
US20180055896A1 (en) 2018-03-01
CN102740870B (zh) 2016-06-29
AU2010258354B2 (en) 2015-08-13
JP2015155468A (ja) 2015-08-27
AU2017202572A1 (en) 2017-05-11
AU2016201525A1 (en) 2016-03-24
JP5712207B2 (ja) 2015-05-07
AU2010258356B2 (en) 2017-01-19
JP5892928B2 (ja) 2016-03-23
JP5689117B2 (ja) 2015-03-25
CN102573865A (zh) 2012-07-11
EP2440223A4 (en) 2012-12-12
JP2017128608A (ja) 2017-07-27
CN102548560A (zh) 2012-07-04
AU2010258352A1 (en) 2012-02-02
US9283255B2 (en) 2016-03-15
JP2012529488A (ja) 2012-11-22
EP2440222A1 (en) 2012-04-18
AU2010258352B2 (en) 2016-04-28
WO2010143058A1 (en) 2010-12-16
US20120082741A1 (en) 2012-04-05
JP2012529487A (ja) 2012-11-22
WO2010143062A1 (en) 2010-12-16
AU2010258354A1 (en) 2012-02-02
JP2012529484A (ja) 2012-11-22
AU2016202674A1 (en) 2016-05-19
EP2440223A1 (en) 2012-04-18
CN102548571A (zh) 2012-07-04
EP2440209A4 (en) 2013-03-20
US20120177759A1 (en) 2012-07-12
AU2010258358B2 (en) 2015-12-10
EP2440220A4 (en) 2012-12-12
CN102497873B (zh) 2016-04-13
AU2017202573B2 (en) 2019-02-21
WO2010143059A1 (en) 2010-12-16
JP2012529485A (ja) 2012-11-22
JP6187831B2 (ja) 2017-08-30
CN102711768B (zh) 2014-04-09
US20120148691A1 (en) 2012-06-14
EP2440209A1 (en) 2012-04-18
JP6076737B2 (ja) 2017-02-08
JP5827618B2 (ja) 2015-12-02
AU2017202572B2 (en) 2019-02-21
AU2010258351B2 (en) 2015-05-21
JP2015164963A (ja) 2015-09-17
WO2010143065A1 (en) 2010-12-16
EP2440221A4 (en) 2012-12-12
CN102548560B (zh) 2016-01-20
AU2010258358A1 (en) 2012-02-02
AU2018202291A1 (en) 2018-04-26
CN102497873A (zh) 2012-06-13
AU2010258351A1 (en) 2012-02-02
US20120077762A1 (en) 2012-03-29
US9050277B2 (en) 2015-06-09
CN102711768A (zh) 2012-10-03
AU2010258355A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
AU2017202572B2 (en) Compositions and methods for prevention and treatment of brain diseases and conditions
Sarmah et al. Sirtuin-1-mediated NF-κB pathway modulation to mitigate inflammasome signaling and cellular apoptosis is one of the neuroprotective effects of intra-arterial mesenchymal stem cell therapy following ischemic stroke
Lin et al. 20 (S)-protopanaxadiol and oleanolic acid ameliorate cognitive deficits in APP/PS1 transgenic mice by enhancing hippocampal neurogenesis
AU2018239239A1 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
CN109908140A (zh) 生物素治疗多发性硬化的用途
Xiao et al. Exercise-induced irisin ameliorates cognitive impairment following chronic cerebral hypoperfusion by suppressing neuroinflammation and hippocampal neuronal apoptosis
Zhang et al. Paricalcitol improves experimental autoimmune encephalomyelitis (EAE) by suppressing inflammation via NF-κB signaling
TWI798320B (zh) 神經系統疾患治療劑
WO2018113027A1 (zh) 白果内酯作为增效剂在制备防治脑神经损伤性疾病药物的应用
US20240000853A1 (en) Lipocalin-type prostaglandin d2 synthase production promoting agent
CN107802621A (zh) 青蒿素b抗神经炎症和治疗神经退行性疾病的用途
AU2015258814A1 (en) Clearance of amyloid ss
Han et al. α7 nicotinic acetylcholine receptor mediates the neuroprotection of remote ischemic postconditioning in a rat model of asphyxial cardiac arrest
Fu et al. Biochanin A, as the Lrg1/TGF-β/Smad2 pathway blockade, attenuates blood-brain barrier damage after cerebral ischemiare-perfusion by modulating leukocyte migration patterns.
CN115192574A (zh) 乌头类生物碱在制备治疗gsdmd相关疾病药物中的应用
WO2009135433A1 (zh) 丹酚总酸和三七总皂苷及其配伍治疗败血症的应用
RU2506950C2 (ru) Комбинация карбостирила и карнитина
US20110224300A1 (en) USE OF POTASSIUM 2-(a- HYDROXYPENTYL) BENZOATE IN THE MANUFACTURE OF MEDICAMENTS FOR PREVENTING AND/OR TREATING SENILE DEMENTIA
CN121943899A (zh) 去氢紫堇鳞茎碱在制备预防和/或治疗动脉粥样硬化药物中的应用
CN116173051A (zh) 人参皂苷Rg-1联合有氧运动在抗抑郁治疗中的应用
TW201618788A (zh) 麥角固醇於製造藥劑之用途
CN117815225A (zh) 氯马斯汀在减轻蛛网膜下腔出血诱导的早期脑损伤及认知功能下降中的应用
CN103656485A (zh) 一种治疗痴呆的中药组合物及其制备方法
CN103656484A (zh) 一种中药组合物及其制备方法与应用
WO2008154794A1 (fr) Utilisation d'extrait de salvia miltiorrhiza pour la préparation d'un médicament pour le traitement de la septicémie

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140827

Termination date: 20170611